Healthcare / Medical DevicesTaipei Exchange
$16.80
-0.10 (-0.59%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 14%
FCF escenarios
weak_data · normalized FCF $-4.9M · quality 28.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
7/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$800M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-7.6%
↓Gross Margin
15.5%
↓Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-11.8%
FCF CAGR
—
FCF margin
-1.4%
FCF / Net income
0.09x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $387.6M · net income $-60.4M · FCF $-5.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $387.6M | $387.6M | $420.5M | $418.5M | $564.6M |
| Net Income | $-60.4M | $-60.4M | $-28.6M | $-48.8M | $28.7M |
| EBITDA | $-47.0M | $-47.0M | $-29.0M | $-43.2M | $14.6M |
| EPS | — | — | -0.66 | -1.13 | 0.66 |
| Gross Margin | 15.5% | 15.5% | 16.6% | 14.5% | 22.7% |
| Operating Margin | -18.2% | -18.2% | -14.0% | -18.2% | -2.7% |
| Net Margin | -15.6% | -15.6% | -6.8% | -11.7% | 5.1% |
| Balance Sheet | |||||
| Current Ratio | 8.91 | 8.91 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-5.2M | $-5.2M | $7.0M | $-4.9M | $-44.2M |
| Returns | |||||
| ROE | -7.6% | -7.6% | -3.3% | -5.3% | 2.8% |
| Valuation | |||||
| P/E | — | — | — | — | 36.57 |
| EV/EBITDA | — | — | — | — | 58.41 |
| P/B | 1.01 | 1.01 | 1.19 | 1.21 | 1.03 |
| Growth & Yield | |||||
| Revenue Growth | -7.8% | -7.8% | 0.5% | -25.9% | — |
| EPS Growth | — | — | 41.6% | -271.2% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-17.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.66 → n/d
Residual
-17.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.